Savolitinib (AZD6094)

Catalog No.S7674 Synonyms: HMPL-504, Volitinib

For research use only.

Savolitinib (Volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase.

Savolitinib (AZD6094) Chemical Structure

CAS No. 1313725-88-0

Selleck's Savolitinib (AZD6094) has been cited by 10 Publications

Purity & Quality Control

Choose Selective c-Met Inhibitors

Other c-Met Products

Biological Activity

Description Savolitinib (Volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase.
Targets
p-Met [1]
(Cell-free assay)
c-Met [1]
(Cell-free assay)
3 nM 5 nM
In vitro

Volitinib has exquisite kinase selectivity and excellent potency[1]. Volitinib displays a highly selective profile across a gastric cell line panel, potently inhibiting cell growth only in those lines with dysregulated cMET (EC50 values 0.6 nM/L-12.5 nM/L)[2]. Volitinib has high membrane permeability without efflux transport across Caco-2 cell monolayer and exhibits negligible P-gp inhibition (IC50 > 17 μM). Volitinib shows no significant reversible or mechanism-based CYP inhibition in human liver microsomes, and no induction of CYP1A2 and CYP3A4 in human hepatocytes[3].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H441 NWXjdZNwTnWwY4Tpc44h[XO|YYm= NEH5NpQyKGh? NIrUUIpKdmirYnn0bY9vKG:oIHOtUYV1KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iTlPJMWg1PDFiY3XscJMh\m:{IEGgbJIh[nliRVzJV2EtKEmFNUC9NE4xODNizszN NXzOc2NsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFgzODlpPkK1NVQ5OjB7PD;hQi=>
NCI-H441 NGDyc2xRem:uaX\ldoF1cW:wIHHzd4F6 MlfSO|IhcA>? NFXGNphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDRzIHPlcIx{KGG|c3Xzd4VlKGG|IFjHSk1qdmS3Y3XkJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByNjFOwG0> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2OEKwPUc,OjVzNEiyNFk9N2F-
Assay
Methods Test Index PMID
Western blot pMET / MET / pAKT / AKT / pERK / ERK 27472392
Growth inhibition assay Cell viability 27472392
In vivo In a mouse pharmacokinetic study (male ICR mice), the clearance of the compound is 4.28 L/(h·kg) and the half-time is 1.7 h. Despite its moderate oral bioavailability (F = 27.2%), the overall plasma exposure is much higher. Volitinib demonstrates dose-dependent tumor growth inhibition in a U87MG subcutaneous xenograft model[1]. Its treatment leads to pharmacodynamic modulation of c-MET signaling and potent tumor stasis in 3/3 cMET-dysregulated gastric cancer patient-derived tumor xenograft models, but has negligible activity in a gastric cancer control model[2]. Volitinib has moderate plasma protein binding rate (60%∼70% in rat, dog, and human; 40% in mouse; 80% in monkey) and exhibits wide distribution to different organs in rat, with high exposures in liver and kidney, very low in brain, spinal cord and testis compared to the plasma level. In PK studies in mouse, rat and dog, Volitinib shows the rapid oral absorption (Tmax<2.5 h) with high exposures and the acceptable bioavailability at 27.2%, 42.6% and 86.3%, respectively. The in vivo clearance (CL) is 11.0, 11.8 and 3.5 mL/min/kg in mouse, rat and dog, respectively, revealing a low extraction ratio. The volume of distribution in steady state (Vss) is 0.4, 1.4 and 1.4 L/kg in those species, respectively, indicating a moderate to low distribution pattern. Volitinib also displays linear pharmacokinetics (PK) in the dose ranges of 1 to 25 mg/kg in rat and 2 to 10 mg/kg in dog. Food hardly affects its PK profile in dog. In contrast, volitinib in monkey shows a notably high extraction ratio (CL=17.2 mL/min/kg) consistent with the in vitro metabolism result. Considering the rapid absorption of volitinib (Tmax=1.9 h) and moderately low distribution (Vss=0.7 L/kg), the poor oral bioavailability (1.9%) of volitinib in monkey is considered to be the result of excessive first-pass extraction. Overall, volitinib exhibits favorable preclinical PK/ADME properties[3].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: NCI-H441 cells
  • Concentrations: --
  • Incubation Time: 1 h
  • Method:

    NCI-H441 cells are plated at a density of 15,000 cells/well in RPMI-1640 medium with 10% FBS in 96-well plates. After incubation overnight, cells are then treated with serially diluted test compounds at 37 ℃ for 1 h. Then the medium is removed, and cells are lysed in 100 μL/well lysis buffer (1% NP-40, 20 mM Tris/pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM activated sodium orthovanadate, 10 mg/mL Aprotinin, 10 mg/mL Leupeptin). The plates containing cell lysate are kept at -80℃ overnight. The next day, the plates are thawed on ice, mixed gently. 25 μL/well of lysates are added into the assay plates pre-coated with anti-p-Met antibody to detect p-c-Met signal. p-c-Met level is determined at 450 nm and 570 nm.

Animal Research:

[1]

  • Animal Models: Female athymic mice
  • Dosages: 1.0, 2.5 and 10.0 mg/kg (oral); 2.5 mg/kg (i.v.)
  • Administration: oral administration/i.v.

Solubility (25°C)

In vitro

DMSO 16 mg/mL
(46.32 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 345.36
Formula

C17H15N9

CAS No. 1313725-88-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05043090 Recruiting Drug: savolitinib|Drug: durvalumab|Drug: sunitinib Papillary Renal Cell Carcinoma AstraZeneca October 28 2021 Phase 3
NCT04606771 Recruiting Drug: Osimertinib + Savolitinib|Drug: Savolitinib + Placebo Non-Small Cell Lung Cancer AstraZeneca September 28 2020 Phase 2
NCT04187456 Completed Drug: Savolitinib|Drug: Midazolam Solid Tumors AstraZeneca|Parexel December 27 2019 Phase 1
NCT04179071 Completed Drug: Savolitinib|Drug: Famotidine Solid Tumours AstraZeneca|Parexel December 13 2019 Phase 1
NCT04121910 Completed Drug: Savolitinib|Drug: Itraconazole Solid Tumour AstraZeneca|Parexel November 7 2019 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Savolitinib (AZD6094) | Savolitinib (AZD6094) supplier | purchase Savolitinib (AZD6094) | Savolitinib (AZD6094) cost | Savolitinib (AZD6094) manufacturer | order Savolitinib (AZD6094) | Savolitinib (AZD6094) distributor